UA99308C2 - Аналог азацитидина и его применение - Google Patents

Аналог азацитидина и его применение

Info

Publication number
UA99308C2
UA99308C2 UAA201004927A UAA201004927A UA99308C2 UA 99308 C2 UA99308 C2 UA 99308C2 UA A201004927 A UAA201004927 A UA A201004927A UA A201004927 A UAA201004927 A UA A201004927A UA 99308 C2 UA99308 C2 UA 99308C2
Authority
UA
Ukraine
Prior art keywords
integer
formula
rchoc
rchnhc
ris
Prior art date
Application number
UAA201004927A
Other languages
English (en)
Ukrainian (uk)
Inventor
Льюис СИЛВЕРМАН
Джеймс Холланд
Марит Лиланд САНДВОЛЬД
Финн МЮРЕН
Оле Хенрик ЭРИКСЕН
Original Assignee
Маунт Синай Скул Оф Медсин
Клавис Фарма Аса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Маунт Синай Скул Оф Медсин, Клавис Фарма Аса filed Critical Маунт Синай Скул Оф Медсин
Publication of UA99308C2 publication Critical patent/UA99308C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Данное изобретение относится к соединениям формулы (I), которая приведена ниже, где R представляет собой Н, RC(O), RCHOC(O) или RCHNHC(O), Rпредставляет собой фрагмент, соответствующий формулам, приведенным ниже, где перекрещивающаяся пунктирная линия, показывает связь, образованную присоединением Rк молекуле формулы (I); Rи Rнезависимо представляет собой ОН или Н, при условии, что Rи Rодновременно не является ОН; Rпредставляет собой Н, RC(O), RCHOC(O) или RCHNHC(O), при условии, что R и Rодновременно не является Н, Rсоответствует общей формуле: CH(CH)(CH=CH-CH)-CH=CH-(CH); k представляет собой целое число от 0 до 7; m представляет собой целое число от 0 до 2; и n представляет собой целое число от 0 до 10; или их фармацевтически приемлемые соли. Раскрыты также способы получения и применения указанных соединений.
UAA201004927A 2007-09-26 2008-09-25 Аналог азацитидина и его применение UA99308C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26

Publications (1)

Publication Number Publication Date
UA99308C2 true UA99308C2 (ru) 2012-08-10

Family

ID=40511851

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201004927A UA99308C2 (ru) 2007-09-26 2008-09-25 Аналог азацитидина и его применение
UAA201004928A UA99836C2 (en) 2007-09-26 2008-09-25 Azacytidine analogue and using thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201004928A UA99836C2 (en) 2007-09-26 2008-09-25 Azacytidine analogue and using thereof

Country Status (15)

Country Link
US (2) US8399420B2 (ru)
EP (2) EP2205073A4 (ru)
JP (2) JP2010540556A (ru)
KR (2) KR20100072230A (ru)
CN (2) CN101815437A (ru)
AU (2) AU2008304381A1 (ru)
BR (2) BRPI0817269A2 (ru)
CA (2) CA2700207A1 (ru)
IL (1) IL204690A0 (ru)
MX (2) MX2010003261A (ru)
NZ (2) NZ583824A (ru)
RU (1) RU2488591C2 (ru)
UA (2) UA99308C2 (ru)
WO (2) WO2009042766A1 (ru)
ZA (1) ZA201001660B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) * 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
KR20100072230A (ko) * 2007-09-26 2010-06-30 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 아자시티딘 유사체 및 이의 용도
PL2299984T3 (pl) 2008-05-15 2019-07-31 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2010014883A2 (en) * 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
AR076418A1 (es) * 2009-04-27 2011-06-08 Reddys Lab Inc Dr Preparacion de decitabina
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
US20120264710A1 (en) * 2011-04-15 2012-10-18 Marit Liland Sandvold Systems and Methods for Detecting hENT1 Expression in Hematological Disorders
US9125884B2 (en) 2011-11-01 2015-09-08 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
BR112014020786A2 (pt) 2012-02-24 2020-10-27 Signal Pharmaceuticals, Llc método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
EP2986321A1 (en) * 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
EP3960182A1 (en) 2015-12-03 2022-03-02 Epidestiny, Inc. Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
MX2019011130A (es) 2017-03-20 2019-11-05 Vaccinex Inc Tratamiento del cancer con un anticuerpo semaforina-4d en combinacion con un agente de modulacion epigenetica.
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CA3097003A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
WO2022035852A1 (en) * 2020-08-10 2022-02-17 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (ru) * 1963-12-22
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) * 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
SU961354A1 (ru) * 1981-02-18 1985-08-07 Институт биоорганической химии АН БССР 3-Фтор-2,3-дидезоксиаденозин,про вл ющий цитостатическую активность
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4981613A (en) 1986-11-04 1991-01-01 Fuji Photo Film Co., Ltd. Laser light source
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
IE980216A1 (en) 1989-04-17 2000-02-23 Scotia Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
JP3101321B2 (ja) * 1991-02-19 2000-10-23 富士通株式会社 酸素を含んだアイソレーション領域を有する半導体装置およびその製造方法
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
CA2115029C (en) * 1991-08-14 2002-03-26 Stanford Salvatore Pelosi, Jr. Cyclic urethanes useful as antiarrhythmic and antifibrillatory agents
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
GB9515279D0 (en) * 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (fr) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Nouveaux composes a base de metaux de transition du groupe 4
CN1198775A (zh) * 1995-08-08 1998-11-11 托马斯杰弗逊大学 重组c－蛋白酶及其加工、方法和用途
WO1997009878A1 (en) 1995-09-15 1997-03-20 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
ATE236188T1 (de) * 1997-01-24 2003-04-15 Conpharma As Gemcitabin-derivate
EP0997473B1 (en) * 1997-06-03 2003-04-09 ITOCHU Techno-Chemical Inc. Natural antitumor or antiviral substances and use of the same
WO1999026958A1 (en) 1997-11-25 1999-06-03 Protarga, Inc. Nucleoside analog compositions and uses thereof
WO1999041231A1 (fr) * 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Derives amidino utilises comme ingredients actifs et medicaments les contenant
AU5073100A (en) 1999-06-09 2001-01-02 Bayer Aktiengesellschaft Pyridine carboxamides and their use as plant protection agents
JP4979866B2 (ja) 1999-09-08 2012-07-18 リガンド・ファーマシューティカルズ・インコーポレイテッド 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
SI1224174T1 (en) 1999-10-15 2003-12-31 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
CA2468099A1 (en) 2001-11-21 2003-05-30 Ganymed 256 Vermogensverwaltungs Gmbh Phospholipid derivatives of nucleosides as antitumoral medicaments
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
CA2499036A1 (en) * 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
WO2004101593A1 (ja) 2003-05-16 2004-11-25 Kissei Pharmaceutical Co., Ltd. ５’−修飾ヌクレオシド誘導体及びその医薬用途
US7244732B2 (en) * 2003-06-20 2007-07-17 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20080033172A1 (en) 2003-12-19 2008-02-07 Koronis Pharmaceuticals, Incorporated Mutagenic Heterocycles
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
EP1713810B1 (en) 2004-02-04 2010-12-29 NeuroSearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20090074848A1 (en) 2005-09-19 2009-03-19 Sharon Johnstone Combination formulations of cytidine analogs and platinum agents
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
KR20100072230A (ko) * 2007-09-26 2010-06-30 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 아자시티딘 유사체 및 이의 용도

Also Published As

Publication number Publication date
ZA201001660B (en) 2011-05-25
US20090209477A1 (en) 2009-08-20
EP2205073A4 (en) 2013-03-06
RU2488591C2 (ru) 2013-07-27
KR20100072230A (ko) 2010-06-30
EP2197274A1 (en) 2010-06-23
KR20100102092A (ko) 2010-09-20
MX2010003002A (es) 2010-07-05
RU2010116154A (ru) 2011-11-10
WO2009042767A1 (en) 2009-04-02
RU2010116274A (ru) 2011-11-10
BRPI0817234A2 (pt) 2014-09-30
EP2205073A1 (en) 2010-07-14
US20090209482A1 (en) 2009-08-20
AU2008304380A1 (en) 2009-04-02
AU2008304381A1 (en) 2009-04-02
CA2700267A1 (en) 2009-04-02
CA2700207A1 (en) 2009-04-02
IL204690A0 (en) 2010-11-30
US8399420B2 (en) 2013-03-19
US8158605B2 (en) 2012-04-17
WO2009042766A9 (en) 2009-05-28
UA99836C2 (en) 2012-10-10
NZ583824A (en) 2012-06-29
CN101815437A (zh) 2010-08-25
NZ583923A (en) 2012-05-25
JP2010540555A (ja) 2010-12-24
WO2009042766A1 (en) 2009-04-02
BRPI0817269A2 (pt) 2014-10-07
MX2010003261A (es) 2010-08-18
CN101877964A (zh) 2010-11-03
EP2197274A4 (en) 2013-03-06
JP2010540556A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
UA99308C2 (ru) Аналог азацитидина и его применение
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2008064018A8 (en) Thienopyrimidinones for treatment of inflammatory disorders and cancers
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MY159260A (en) Pharmaceutical composition and poria extract useful for enhancing absorption of nutrients
TW200720260A (en) Prokineticin 1 receptor antagonists
TW200716566A (en) Prokineticin 2 receptor antagonists
TW200745122A (en) New compounds I
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
TW200716547A (en) Piperidin-4-yl-amide derivatives
WO2005084222A3 (en) Synthesis of epothilones, intermediates thereto, analogues and uses thereof
JO2478B1 (en) (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
TW200621260A (en) Selected fused heterocyclics and uses thereof
WO2007128829A3 (en) 18,21-didesoxymacbecin derivatives for the treatment of cancer
WO2007095021A3 (en) Novel compounds
WO2004087673A3 (en) Migrastatin analogs and uses thereof
WO2009027736A3 (en) 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.